Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Owners Of Ayrshire Meat Processing Plant Fined ÷£30,000 After Worker Loses Three Fingers In Machinery
The owners of a Prestwick meat processing plant have been convicted of failing to have a safe isolation procedure in place for machinery, after a worker lost three fingers when a machine he was attempting to repair started up.
generic viagra online
Being Overweight With Heart Risk In Mid Life Followed By Weight Loss Linked To More Illness And Higher Risk Of Death Later
Researchers in Finland who tracked the health of over 1,000 men from middle age into old age found that being overweight and having high risk
News of the day
AOSSM Presents Prestigious Research Awards
In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present eight research awards and two grants during its Annual Meeting, July 9-12th in Keystone, Colorado. As a leader in orthopaedic sports medicine, AOSSM annually provides more than $150,000 to research initiatives and projects around the country. Highlights of this year"s award recipients include:
Public Health

Roswell Park Researchers Evaluate Promising Drug For Intolerant Or Resistant CML

Roswell Park Cancer Institute (RPCI) scientists are investigating a promising drug for chronic myeloid leukemia (CML) patients who have become intolerant or resistant to standard therapies. Meir Wetzler, MD, Department of Medicine at Roswell Park Cancer Institute, analyzed the effectiveness of omacetaxine (OM) in an ongoing phase II clinical study and will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL. "Subcutaneous Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors (TKIs): Data from an Ongoing Phase II Trial" Friday, May 29 - 5 pm EST Level 2, West Hall F1 Cancer therapies that target specific proteins have become standard treatment for patients diagnosed with chromic myeloid leukemia. A protein, BCR-ABL, causes CML cells to grow and reproduce out of control. Drugs that target BCR-ABL are known as tyrosine kinase inhibitors (TKIs). Roswell Park investigators, under the direction of Dr. Wetzler, evaluated omacetaxine in 60 patients who had failed at least two TKIs. Sixty-five CML patients participated in this phase II clinical study. Dr. Wetzler and colleagues report patients experienced treatment responses in both the white blood cells (hematologic) and the marrow cells (cytogenetic). Eighty percent of the chronic-phase patients experienced a complete hematologic response (CHR) rate and no disease progression for a median of 7.5 months. In this same group, 20% had a major cytogenetic response rate, and median response to disease progression was 2.7 months. For study patients in the accelerated phase, a 60% CHR rate was observed, with a median of 8.9 months without disease progression; and for blast phase patients, a CHR rate was 40%, with a median duration of 5.7 months. Dr. Wetzler reports that omacetaxine is generally well tolerated and that most side effects are reversible. "Targeted therapies have changed the treatment approach and improved survival rates for patients diagnosed with chronic myeloid leukemia. However, patients who develop resistance to these therapies have few options. Omacetaxine is among the next generation of novel therapies that may offer hope for those patients," said Dr. Wetzler. Roswell Park Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009